B7H5于口腔颌面头颈肿瘤免疫治疗中作为联合用药靶点的应用潜力探究  

Application potential exploration of B7H5 used as drug combination target in the immunotherapy of oromaxillofacial head and neck tumor

作　　者：赵昊明 赵华强[1,2] ZHAO Haoming;ZHAO Huaqiang(The Department of Oral and Maxillofitcial Surgery,School of Stomatology,Shandong University,Ji＇an 250012,China)

机构地区：[1]山东大学口腔医院口腔颌面外科,山东济南250012 [2]山东大学口腔医学院,山东济南250012

出　　处：《口腔医学》2018年第11期1048-1052,共5页Stomatology

基　　金：山东省自然科学基金面上项目(ZK2014HM041)

摘　　要：利用负性调节因子(NCR)进行肿瘤免疫治疗是目前口腔头颈肿瘤研究的一大热点。临床试验证明,相对于化疗药物,抗负性调节因子靶向药的疗效更加显著且对机体的伤害性更小。但随着肿瘤耐药机制研究的日趋深入,发现了大量针对靶向药物的肿瘤耐药案例,因而临床越来越强调联合用药,以期在降低肿瘤耐药及细胞毒性的同时,保证足够的治疗效果。B7H5,又名VISTA,是B7-CD28家族成员之一,与负性调节因子CTLA-4、PD-1、PD-L1等存在极高的同源性,亦属于NCR家族。目前关于B7H5免疫抑制方面的机制仍尚未完全阐明,其分子结构提示可能成为一个理想的联合用药靶点。本文就关于B7H5分子在口腔颌面头颈肿瘤免疫治疗方面的研究现状作一综述。Utilization of negative checkpoint regulatm＇s （NCRs） for immunotherapy has garnered significant interest of oral head and neck tumor research. Compared to chemotherapy, the anti-NCRs targeted drugs are more effective and less harmful with the demonstration of clinical trials. However, with the research of tumor resistance mechanism becoming more and more intensive, myriad tumor resistance cases have appeared for targeted drugs. Therefore, more and more emphasis is focused on eomhination therapy in order to reduce the resistance and cytotoxicity, and to ensure adequate therapeutic effect. BTH5, also named VISTA （V-domain Ig-containiug Suppressor of T cell Activation） , is a member of B7-CD28, which has sky-high homology with negative checkpoint factors CTLA-4, PD-1, PD-L1, and is also a member of NCR. At present, the immunosupression mechanism of B7H5 has not been clarified, whose molecule may become an ideal drug combination target. The article reviews the research status of B7H5 molecule in the immunotherapy of oromaxilofacial head and neck tumor.

关 键 词：B7H5(VISTA) 负性调节因子(NCR) 抗肿瘤免疫治疗 肿瘤免疫抑制微环境 肿瘤免疫编译 

分 类 号：R739.8[医药卫生—肿瘤]